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Pimecrolimus Enhances TLR2/6-Induced Expression
of Antimicrobial Peptides in Keratinocytes
Amanda S. Bu¨chau1, Ju¨rgen Schauber1, Thomas Hultsch2, Anton Stuetz3 and Richard L. Gallo1
Calcineurin inhibitors are potent inhibitors of T-cell-receptor mediated activation of the adaptive immune
system. The effects of this class of drug on the innate immune response system are not known. Keratinocytes
are essential to innate immunity in skin and rely on toll-like receptors (TLRs) and antimicrobial peptides to
appropriately recognize and respond to injury or microbes. In this study we examined the response of cultured
human keratinocytes to pimecrolimus. We observed that pimecrolimus enhances distinct expression of
cathelicidin, CD14, and human b-defensin-2 and b-defensin-3 in response to TLR2/6 ligands. Some of these
responses were further enhanced by 1,25 vitamin D3. Pimecrolimus also increased the functional capacity of
keratinocytes to inhibit growth of Staphylococcus aureus and decreased TLR2/6-induced expression of IL-10 and
IL-1b. Furthermore, pimecrolimus inhibited nuclear translocation of NFAT and NF-kB in keratinocytes. These
observations uncover a previously unreported function for pimecrolimus in cutaneous innate host defense.
Journal of Investigative Dermatology (2008) 128, 2646–2654; doi:10.1038/jid.2008.135; published online 22 May 2008
INTRODUCTION
Topical immunomodulators, such as the macrolactam
ascomycin pimecrolimus, are effectively used for treating
atopic dermatitis and other inflammatory skin diseases
(Grassberger et al., 2004; Novak et al., 2005; Stuetz et al.,
2006). These drugs bind to immunophilins, inhibit the serine/
threonine phosphatase calcineurin, and subsequently prevent
nuclear translocation of nuclear factor of activated T cells
(NFAT). As a consequence of the inhibition of NFAT, the
transcription of proinflammatory cytokines is suppressed in
T cells (Dumont, 2000). It is this inhibitory action on the
function of T cells that has been presumed to explain clinical
effectiveness. Recent advances in the understanding of the
innate immune functions of the skin have opened new
avenues to further study the mechanism(s) of action of
calcineurin inhibitors on the physicochemical and immuno-
logical barrier function of the epidermis. The effects of
pimecrolimus on keratinocyte driven innate immune re-
sponses constitute an area of interest.
Immunophilins, calcineurin, and NFAT are also expressed
in the cells of the innate immune system, including epidermal
keratinocytes (Al-Daraji et al., 2002), but their function is
incompletely understood. An important innate immune
function of keratinocytes is their capacity to provide
a chemical barrier against infection by production of
peptides with antimicrobial activity. All epithelial and many
non-epithelial cells produce these antimicrobial peptides
(AMPs). In keratinocytes, AMPs such as cathelicidins and
b-defensins have been studied most extensively as effectors
of innate immune protection (Frohm et al., 1997; Turner
et al., 1998; Agerberth et al., 2000; Di Nardo et al., 2003;
Zanetti, 2005). Cathelicidins and human b-defensins
(HBDs) have broad-spectrum antimicrobial activity and addi-
tional immunomodulatory functions. The clinical importance
of AMPs has been made evident from studies showing that
they are essential in inflammatory processes such as
infection, wound healing, psoriasis, and rosacea (Ong
et al., 2002; Heilborn et al., 2003; Schauber et al., 2007;
Yamasaki et al., 2007). Deficiency of AMPs is observed in
patients with atopic dermatitis and Kostmann syndrome, and
this lack of appropriate AMP production leads to bacterial
and viral superinfections (Ong et al., 2002; Pu¨tsep et al.,
2002).
Superinfections seen in atopic dermatitis patients are
frequently caused by Staphylococcus aureus (Leung et al.,
2004), a Gram-positive bacterium that activates the Toll-like
receptor-2(TLR2)-signaling pathway. TLR activation has been
demonstrated to induce innate immune response in epider-
mal keratinocytes and can be potent stimuli of cytokine
release and HBD production, but stimulate cathelicidin
expression only weakly (Kumar et al., 2006; Schauber
et al., 2006; Sumikawa et al., 2006; Schlee et al., 2007).
In human keratinocytes, optimal cathelicidin expression
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requires activity of 1,25-(OH)2 vitamin D3 (1,25D3) (Wang
et al., 2004; Liu et al., 2006; Schauber et al., 2007).
Recent studies attempting to understand better the
elements that control innate immune functions such as
AMP production have shown that innate and adaptive
immune responses are controlled by distinct, and sometimes
contrasting, mechanisms. We also know now that many cell
types express NFAT and, therefore, may also be targeted by
calcineurin inhibitors (Ho et al., 1994; Aramburu et al., 1995;
Monticelli et al., 2004; Goodridge et al., 2007). For example,
recent findings reported that calcineurin inhibition had
unexpected effects on natural killer cells, showing that
calcineurin inhibition enhances, rather than suppressing,
cytotoxic natural killer cell function (Wang et al.,
2007). Therefore, on the basis of the complex, and
incompletely understood, mechanism for regulation of AMP
expression, we investigated the effects of pimecrolimus on
AMP expression and function, expression of TLRs, and
cytokine production by human keratinocytes. To our know-
ledge, it is previously unreported that pimecrolimus can
amplify innate immune functions of keratinocytes by affect-
ing distinct AMP expression and pathogen recognition in the
presence of TLR ligands and/or 1,25D3. Our observations
uncover previously unknown functions for pimecrolimus in
cutaneous innate host defense and further highlight the
complexity of the innate and adaptive immunoregulatory
systems in the skin.
RESULTS
Pimecrolimus enhances antimicrobial peptide expression in
human keratinocytes
Calcineurin inhibitors such as pimecrolimus suppress multi-
ple components associated with the immune function of
leukocytes, but it is unknown whether this also inhibits the
innate immune responses of epithelia, such as expression of
AMPs or signaling by TLRs. To test whether pimecrolimus
influences AMP production following TLR activation, NHEKs
were stimulated with TLR ligands in the presence or absence
of pimecrolimus. Normal human epidermal keratinocytes
(NHEKs) incubated with TLR2 and TLR4 responded with an
increase in cathelicidin mRNA in response to pimecrolimus
(Figure 1a). The combination of Malp-2 (a selective TLR2/6
ligand) and pimecrolimus induced strongest expression of
cathelicidin among all TLR ligands tested. The increase in
cathelicidin mRNA induced by Malp-2 and pimecrolimus
was accompanied by an increase in the expression of
cathelicidin protein as determined by immunfluorescence
(Figure 1b). Other microbial products that can stimulate
NHEK, such as poly-I:C (TLR3 ligand), staphylococcal
enterotoxin B, or staphylococcus protein A, did not change
cathelicidin gene expression of NHEKs with or without the
presence of pimecrolimus (data not shown).
To test whether other antimicrobial peptides produced
by NHEKs were also affected by pimecrolimus treatment,
HBD2 and HBD3 mRNA expression was analysed. Pime-
crolimus in combination with the TLR2/6 ligand Malp-2
significantly enhanced HBD2 expression, whereas addition
of pimecrolimus downregulated lipoteichoic acid- and
lipopolysaccharide-induced HBD2 gene expression (Figure 1c).
Pimecrolimus also increased HBD3 expression in the
presence of peptidoglycan and Malp-2, whereas presence
of pimecrolimus slightly, but significantly, downregulated
lipoteichoic acid-induced expression of this AMP. Thus,
results shown here demonstrate that pimecrolimus affects
distinct TLR responses and results in different AMP innate
immune responses in keratinocytes.
Pimecrolimus increases TLR and CD14 expression in human
keratinocytes
Of the compounds tested, TLR2/6 ligands were seen to
induce the greatest increase of AMPs in NHEKs treated with
pimecrolimus. The expression of TLR2, CD14 (a TLR2 and
TLR4 co-recognition molecule; Jiang et al., 2005), and
cathelicidin has also been found to be enhanced by 1,25D3
(Wang et al., 2004; Liu et al., 2006; Schauber et al., 2007).
Analysis of cathelicidin and CD14 showed pimecrolimus
enhanced the 1,25D3 induction of these genes (Figure 1e).
Therefore, we explored next the effects of pimecrolimus on
the expression of selective TLRs in keratinocytes and
included 1,25D3 as a stimulus. NHEKs were treated with
pimecrolimus (10 nM) and 1,25D3 (1 nM), and transcript
abundance of TLR1, TLR2, TLR6, and CD14 was analyzed
by reverse transcriptase–PCR (qPCR). Treatment of NHEKs
with pimecrolimus alone resulted in a significant increase in
TLR6 and CD14 as compared with that in vehicle-treated
controls. Combination of 1,25D3 and pimecrolimus signifi-
cantly increased TLR2 and resulted in pronounced upregula-
tion of CD14. The increase in CD14 mRNA abundance by
1,25D3 and pimecrolimus was accompanied by an increase
in CD14 protein expression as determined by western blot
analysis (Figure 2b and c).
To further explore the significance of the increased
responsiveness to TLR2 stimulation, and amplify the re-
sponse, cathelicidin and CD14 expression was examined in
the presence of pimecrolimus in combination with 1,25D3
and/or Malp-2 (Figure 2d). Pimecrolimus (10 nM) increased
cathelicidin expression approximately 40-fold in the pre-
sence of 1,25D3 (1 nM), and this was further enhanced when
combinations of 1,25D3 and Malp-2 (0.1 mgml1) were used.
Similar results were observed for CD14 expression and
showed an approximately 100-fold increase in the presence
of 1,25D3 and pimecrolimus (Figure 2d).
Pimecrolimus enhances 1,25D3-induced cathelicidin mRNA
in a dose-dependent manner
To examine the dose responsiveness of NHEKs to pimecro-
limus, cells were stimulated with a low dose of 1,25D3 (1 nM)
in the presence of a wide range of concentrations of
pimecrolimus. Cathelicidin and CD14 expression increased
in a dose-dependent manner, with maximum response in the
range of 1 to 50 nM pimecrolimus (Figure 3a and b). Doses
below or above this range had lesser effect. To determine
whether pimecrolimus induced cell cytotoxicity, cell death
was determined by lactate dehydrogenase release and
annexin V/propidium iodide staining. Pimecrolimus did not
induce cell cytotoxicty as evaluated by either assay (data not
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shown). Other calcineurin inhibitors, including FK506 and
cyclosporin, also induced a dose-dependent increase in the
expression of cathelicidin when stimulated by 1,25D3. Here,
the maximal inducing effect on cathelicidin gene expression
was found between 0.1 and 1 nM for FK506, and between
10 and 50 pgml1 for cyclosporine A (Figure 3c and d).
Thus, the results presented here suggest that immunophillin
binding drugs stimulate the innate immune AMP response
of keratinocytes in a dose-dependent manner. This enhancing
effect on the innate immune response was unexpected given
the well-established immunosuppresive action of these
molecules on adaptive immune responses.
Differential effects of pimecrolimus on Malp-2-induced
cytokine expression from human keratinocytes
Since much of the prior characterization of the immuno-
suppressive effects of immunophilin-binding or calcineurin-
inhibiting molecules has focused on T-cell cytokine and
chemokine responses, we next sought to evaluate the effects
of these drugs on these events in human keratinocytes;
Malp-2 is a TLR2/6-dependent microbial stimulus inducing
a cytokine response in keratinocytes. Therefore, NHEKs were
treated with the vehicle, Malp-2, pimecrolimus, or the
combination of Malp-2 and pimecrolimus, and expression
of IL-10, IL-1b, IL-6, and IL-8 (CXCL8) was determined by
Malp-2Control
Malp-2 + pimecrolimusPimecrolimus
LPSMalp-2LTAPGNControl
LPSMalp-2LTAPGNControl LPSMalp-2LTAPGNControl
Cathelicidin
– pimecrolimus
+ pimecrolimus
– pimecrolimus
+ pimecrolimus
– pimecrolimus
+ pimecrolimus
30
20
10
0
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e)
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e)
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e)
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e)
*
***
**
***
***
***
**
* *
ns
HBD2 HBD3
850
600
350
100
10
8
6
4
2
35
30
25
20
15
10
5 ***
**
***
**
**
*
*
ns ns
CD14Cathelicidin
350
250
150
50
8
6
4
2
0
3,000
2,500
2,000
1,500
150
100
50
0
+
+
+
+
+
+
++
++
–
+
+
– ––
–
+
–
–
–
–
–
–
–
– –
+
–
–
+
+
–
+
+
–
1,25D3
pimecrolimus
Malp-2
a
c
e
d
b
Figure 1. Pimecrolimus enhances antimicrobial peptide and CD14 expression in human keratinocytes. Expression of mRNA for (a) cathelicidin, (c) HBD2, and
(d) HBD3 was evaluated in NHEKs that were stimulated with TLR ligands in the presence or absence of pimecrolimus (10 nM) for 24 hours. Peptidoglycan
(1 mgml1), lipoteichoic acid (10 mgml1), Malp-2 (0.1 mgml1), or lipopolysaccahride (0.1mgml1) were used for selective TLR activation. (b) Protein
expression of cathelicidin was evaluated in NHEKs grown on chamber slides. Cells were stimulated with the vehicle (control), Malp-2 (0.1mgml1),
pimecrolimus (10 nM), or their combination. Cells were stained with anti-LL-37 antibody and nuclei were detected with 4,6-diamidino-2-phenylindole.
Bar¼50 mm (a, c, d, e). (e) Expression of mRNA for cathelicidin or CD14 in presence of low dose 1,25OH vitamin D (1 nM) combined with pimecrolimus (10 nM)
and/or Malp-2 (0.1mgml1). mRNA abundance was evaluated by real-time qPCR and was normalized to that of vehicle-treated controls. Data are means
of triplicates (þ SD) from a single experiment representative of at least two. Significances were calculated by unpaired Student’s t-test, with *Po0.05, **Po0.01,
and ***Po0.001.
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qPCR. In contrast to enhanced AMP response, pimecrolimus
suppressed the expression of IL-10 and IL-1b when stimulated
by Malp-2 (Figure 4a). Similarly to these results, cell
stimulation, including FK506 and cyclosporin A, also resulted
in a decrease of IL-1b when stimulated by Malp-2 (Figure 4b).
On the other hand, IL-6 and IL-8 expression was not inhibited
and a small increase was detected. Expression of IL-4 and
IL-17 was undetectable by qPCR in NHEKs (data not shown).
Thus, these findings show that pimecrolimus selectively
affects cytokine production in human keratinocytes, and
these effects differ from the effects on AMPs and TLR
expression.
Pimecrolimus enhances the ability of human keratinocytes to
kill S. aureus
To determine whether the increase in AMP and TLR
expression induced by pimecrolimus results in a change in
the functional capacity of NHEK to kill bacteria, we next
measured the antimicrobial killing activity of NHEKs against
S. aureus. Total AMP activity was assessed by preparing
lysates of NHEKs following treatment with test stimuli and
then adding these lysates to actively growing cultures of
S. aureus strain Dmprf. Pimecrolimus treatment significantly
increased the antimicrobial activity of keratinocytes treated
with 1,25D3 or Malp-2 (Figure 5a). As pimecrolimus is a
derivate of the macrolactam ascomycin, we also examined
whether pimecrolimus alone had antimicrobial activity in this
assay. Pimecrolimus did not inhibit bacterial growth when
added alone to bacterial cultures (Figure 5b).
Pimecrolimus inhibits Malp-2-induced nuclear translocation
of NFAT and NF-jB in human keratinocytes
In T cells, the classical mechanism suggested for the
immunosuppressive effects of calcineurin inhibition is
through inhibition of NFAT translocation into the nucleus
(Clipstone and Crabtree, 1992). The function of NFAT in
keratinocytes has not been studied well. Therefore, we
evaluated whether pimecrolimus inhibits nuclear transloca-
tion of NFAT and also examined the response of nuclear
factor-kB (NF-kB), a transcription factor important to the
immune response of many cell types, including keratinocytes
(Karin, 2006; Rebholz et al., 2007). NHEKs were grown on
chamber slides and localization of either NFAT or NF-kB was
evaluated directly by immunostaining. In vehicle-treated
NHEKs, staining of NFAT and NF-kB was observed in the
cytoplasm of cells, with a perinuclear localization. Cells
treated with Malp-2 (0.1 mgml1) alone showed increased
nuclear staining of NFAT (Figure 6a) and NF-kB (Figure 6b).
Pimecrolimus inhibited nuclear translocation of both NFAT
and NF-kB following Malp-2 stimulation. Pimecrolimus at a
concentration of 10 nM did not induce detectable changes in
the cytoplasmic localization of NFAT or NF-kB in the
absence of Malp-2.
DISCUSSION
Pimecrolimus cream (1%) is a topical formulation of a
macrolactam ascomycin. It is used for treatment of atopic
dermatitis. The mechanism of action of pimecrolimus in
atopic dermatitis is not fully understood. It has been
demonstrated that pimecrolimus binds with high affinity to
macrophilin-12 (FK506-binding protein-12) and inhibits the
activity of the calcium-dependent phosphatase, calcineurin.
As a consequence, it inhibits T-cell activation by blocking
the transcription of early cytokines. In particular, pimecroli-
mus inhibits at nanomolar concentrations IL-2 and IFN-g
(Th1-type) and IL-4 and IL-10 (Th2 type) cytokine synthesis
in human T cells. In addition, pimecrolimus prevents
release of inflammatory cytokines and mediators from mast
cells in vitro after stimulation by antigen/IgE. While the
preceding inhibitory effects have been observed, the clinical
significance of these observations in atopic dermatitis is
not known.
Recent advances in our understanding of the immune
defense system of the skin inspired this investigation into the
response of keratinocytes to pimecrolimus. Here we report
the results of a series of first studies on the effect of this
calcineurin inhibitor on keratinocyte-driven antimicrobial
and other innate immune responses. Unexpectely, low
concentrations of pimecrolimus enhanced expression of
activation markers of the innate immune response in human
keratinocytes. Specifically, expression of AMPs stimulated by
1,25D3 and/or Malp-2,and CD14 expression were enhanced.
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Figure 2. Pimecrolimus enhances TLR and CD14 expression in
keratinocytes. NHEKs were stimulated with vehicle control, low-dose
1,25D3 (1 nM), pimecrolimus (10 nM), or the combination of 1,25D3 and
pimecrolimus for 24 hours. (a) Gene expression of TLR1, TLR2, TLR6 ,and the
TLR cofactor CD14 was analyzed by real-time qPCR. (b) Western blotting of
CD14 protein expression (upper blot) in NHEKs stimulated with vehicle
(lane 1), 1,25D3 (1 nM, lane 2), pimecrolimus (10 nM, lane 3), or the
combination of 1,25D3 and pimecrolimus (lane 4) for 24 hours. Membranes
were reprobed for loading control with an anti-a-tubulin antibody
(lower blot). (c) Protein abundance of CD14 seen in western blot was
quantified by densitometry. (d) Pimecrolimus enhanced cathelicidin and
CD14 gene expression in the presence of low-dose 1,25D3 (1 nM) or the
combination of 1,25D3 and the TLR2, TLR6 ligand Malp-2 (0.1 mgml1)
for 24 hours. Significances were calculated by unpaired Student’s t-test,
with *Po0.05, **Po0.01, and ***Po0.001. ND, not detectable.
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Pimecrolimus treatment resulted in an increase in the
capacity of keratinocytes to suppress the growth of S. aureus.
These findings are consistent with the notion of distinct
regulatory systems governing adaptive and innate immune
responses, namely: enhancement of innate immune response
while ‘‘silencing’’ an adaptive immune response.
Pimecrolimus is used as an immunosuppressive drug for
treatment of atopic dermatitis and other inflammatory skin
diseases. However, to our knowledge, the effects of
pimecrolimus on innate immune responses have never been
studied. The goal of this study was to identify how
pimecrolimus affects innate antimicrobial host defence
mechanisms of keratinocytes. Pimecrolimus enhanced AMP
expression stimulated by 1,25D3 and/or Malp-2, increased
CD14 expression, and resulted in an increase in the capacity
of keratinocytes to suppress the growth of S. aureus. These
findings are contrary to expectations for a drug with potent
immunosuppressive action on T cells, but not inconsistent
with the distinct regulatory systems that have been uncovered
for adaptive and innate immune responses. Our findings
highlight the unique regulatory mechanisms that are active in
epithelial antimicrobial function and suggest that the
accepted model for action of topical immunomodulating
drugs should be revisited.
Results presented here suggest that pimecrolimus can
amplify multiple and distinct innate immune responses in
keratinocytes. Host defense events that were measured
included the expression of three independently regulated
antimicrobial peptides, the expression of the pattern recogni-
tion receptor CD14, and the total antimicrobial activity of
keratinocyte lysates. Pimecrolimus enhanced all of these
indicators when present in combination with TLR2/6 ligand
and/or in the presence of 1,25D3. TLR2 activation and the
vitamin D pathway have been linked by recent findings that
TLR2,6 stimulation in keratinocytes initiates the production of
active 1,25D3 through upregulation of the converting
enzyme CYP27B1 and subsequent 1-hydroxylation of stored
25D3. Our current findings demonstrate that the combination
of pimecrolimus and 1,25D3 resulted in a stronger AMP
response than that by pimecrolimus and Malp-2 alone. Thus,
these findings suggest that pimecrolimus might also be
involved in 1,25D3 signaling, or that the actions of
pimecrolimus may modify genes also regulated by 1,25D3.
A possible explanation for this might be found in revealing
the genomic effects mediated by 1,25D3. Genomic effects of
1,25D3 are mediated by its nuclear hormone receptor, the
vitamin D receptor, which acts as a transcription factor by
binding to vitamin D-responsive elements in the promoter of
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Figure 3. Dose-dependent effect of pimecrolimus, FK506, and cyclosporin A on cathelicidin and CD14 expression in keratinocytes. (a, b) Cathelicidin
and CD14 expression was evaluated in NHEKs that were stimulated with increasing concentrations of pimecrolimus in the presence or absence of 1,25D3 (1 nM)
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responsive genes (Nagpal et al., 2005). Vitamin D-receptor
ligand interaction mediates the regulation of transcription in
at least three different ways: (1) it can positively regulate the
expression of certain genes by binding to vitamin D-
responsive elements, (2) it can negatively regulate the
expression of other genes by binding to negative vitamin D-
responsive elements, or (3) it can inhibit the expression of
some genes by antagonizing the action of certain transcrip-
tion factors, such as NFAT and NF-kB (Nagpal et al., 2005).
The latter mechanism is thought to be mediated by
competition of vitamin D receptor with NFAT for binding to
the composite NFAT1-activator protein-1 enhancer motif and
consequent interaction with c-Jun (Alroy et al., 1995;
Takeuchi et al., 1998; Towers and Freedman, 1998). Also,
it has been shown recently that 1,25D3 can affect NF-kB
activity by inhibiting de novo synthesis of the NF-kB p50
protein and its precursor p105 in human lymphocytes
(Yu et al., 1995), and by downregulation of c-Rel and Rel B
in dendritic cells (Xing et al., 2002). Involvement of NFAT
and/or NF-kB in 1,25D3-mediated effects may be part of a
pathway by which 1,25D3 exerts its effects by targeting
transcription factors other than the vitamin D receptor. Thus,
inhibition of the NFAT- and NF-kB-signaling pathway by
pimecrolimus might lead to enhancement of 1,25D3-
mediated innate immune responses as those observed in this
study.
As to the molecular mechanism of action in human
keratinocytes, the data suggest that the stimulatory effects of
pimecrolimus are due to NFAT and/or NF-kB acting as
negative regulators of cathelicidin transcription and certain
TLR-signaling events. In line with this hypothesis are findings
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Significances were calculated by unpaired Student’s t-test, with *Po0.05,
**Po0.01, and ***Po0.001.
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Figure 5. Antimicrobial activity of human keratinocytes increases with
pimecrolimus. (a) NHEKs were stimulated with vehicle, pimecrolimus
(10 nM), 1,25D3 (1 nM), Malp-2 (0.1 mgml1), or the combination thereof for
24 hours. Cell lysates were prepared as described under Materials and
Methods, then added to approximately 20 103 CFUs S. aureus DmPRF.
Bacterial growth was monitored over time by measurement of absorbance of
culture at OD600. Data after 8 hours incubation are displayed. (b) To
determine whether pimecrolimus itself has antimicrobial activity, it was
directly incubated with bacterial cultures of S. aureus DmPRF and bacterial
growth was monitored over time by OD600. Data are means of triplicates
(þ SD) from one experiment. Significances were calculated by unparied
Student’s t-test, with *Po0.05, **Po0.01.
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b
Figure 6. Pimecrolimus suppresses NFAT and NF-jB nuclear translocation
in human keratinocytes. NHEKs grown on chamber slides were pretreated
with the vehicle alone or with various concentrations of pimecrolimus
for 30minutes before stimulation with vehicle or Malp-2 (0.1 mgml1)
for 16 hours. NHEKs were fixed and stained with an (a) anti-NFAT1 or
(b) anti-NF-kB antibody as described under Materials and Methods to
evaluate the pattern intracellular localization. Bar¼50 mm.
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that the human cathelicidin promoter has putative NFAT- and
NF-kB-binding sites (Pestonjamasp et al., 2001). Precedence
exists for negative regulatory elements in the cathelicidin
promoter (Wu et al., 2002). In contrast to this, it has been
reported that defensin’s expression can be induced by NF-kB
activation (Wehkamp et al., 2004, 2006).
Recently, it has been reported that pimecrolimus and
tacrolimus can induce release of the neuropeptides substance
P and calcitonin gene-related peptide from nerve fibers,
which in turn leads to degranulation of mast cells (Stander
et al., 2007). The authors suggest that pathways others than
NFAT inhibition could be affected by pimecrolimus and
tacrolimus. Similar pathways could be also affected in
keratinocytes leading to amplification of the innate immune
response. Hence, it remains to be determined which
elements affected by pimecrolimus are involved in governing
innate immune responses in keratinocytes. Candidates for
analysis, therefore, include the immunophilins, calcineurin,
NFAT, NF-kB, or other >hitherto unknown elements.
In conclusion, the observations presented in this study
reveal a previously unknown observation in the regulation of
innate immune function, suggest new areas for investigation of
the mechanism of TLR and AMP responses, and might lead to
new treatments. Various calcineurin inhibitors have proven
clinical utility as therapeutic agents against inflammation and
autoimmunity. Antimicrobial peptides can suppress the func-
tion of dendritic cell and are also important modifiers of the
cutaneous inflammation and immune defense (Davidson et al.,
2004; Bowdish et al., 2005; Di Nardo et al., 2007; Lande et al.,
2007; Yamasaki et al., 2007). It is intriguing to speculate that
part of the therapeutic benefit of these drugs has been though
unrecognized effects on the function of the innate immune
system. Targeted treatment of keratinocytes may offer oppor-
tunities for anti-infective therapy in combination with inhibition
of inflammation. Future work is required to extend the current
findings to in vivo systems and further define the signaling
system responsible for these observations.
MATERIALS AND METHODS
Cell culture and stimuli
Normal human keratinocytes were grown in serum-free EpiLife cell
culture media (Cascade Biologics, Portland, OR) containing 0.06mM
Ca2þ and 1 EpiLife defined growth supplement with the addition of
50Uml1 penicillin and 50mgml1 streptomycin at 37 1C under
standard tissue culture conditions. Cell cultures were maintained for
up to four passages in this media and media changes were performed
every other day. Cells at a confluence of 60–80% were stimulated with
1,25D3 (Sigma, St Louis, MO), pimecrolimus (Novartis, East Hanover,
NJ), FK506 (Sigma), cyclosporin A (Sigma), Malp-2 (0.1mgml1; Alexis,
Carlsbad CA), peptidoglycan (1mgml1; Invivogen, Sorrento Valley,
CA), lipoteichoic acid (10mgml1; Sigma), poly-I:C (25mgml1;
Amersham, Piscataway, NJ), lipopolysaccharide (0.1mgml1; Sigma),
Staphylococcus eneterotoxin B (10ngml1; Sigma), or Staphylococcus
protein A (10mgml1; Calbiochem, San Diego, CA).
Real-time qPCR
After cell stimulation, total RNA was extracted using Trizol
(Invitrogen, Carlsbad, CA) and 1mg RNA was reverse transcribed
using iScript (Bio-Rad, Hercules, CA). The expression of cathelicidin
was evaluated using an FAM-CAGAGGATTGTGACTTCA-MGB
probe, using primers 50-CTTCACCAGCCCGTCCTTC-30 and 50-CCA
GGACGACACAGCAGTCA-30. For expression of glyceraldehyde-
3-phosphate dehydrogenase, a VIC-CATCCATGACAACTTTGGTA-
MGB probe with primers 50-CTTAGCACCCCTGGCCAAG-30
and 50-TGGTCATGAGTCCTTCCACG-30 was used as described
(Schauber et al., 2006). Predeveloped Taqman assay probes (Applied
Biosystems ABI, Foster City, CA) were used for analyzing the
expression of HBD2, HBD3, CD14, TLR1, TLR2, TLR6, IL-8, IL-10,
IL-1b, IL-4, and IL-17. All analyses were performed in triplicate, and
were independent cell stimulation experiments performed with an
ABI Prism 7000 Sequence detection system. Fold induction relative
to the vehicle-treated control was calculated using 2(DDCt) method,
where DCt¼DCt(stimulant)DCt(vehicle), DCt¼Ct(target gene)Ct(GAPDH),
and Ct is the cycle at which detection threshold is crossed.
Fluorescence immunohistochemistry
NHEKs were grown on chamber slides and stimulated with
pimecrolimus, Malp-2, their combination, or the vehicle. After
acetone fixation and subsequent washings in phosphate-buffered
saline, slides were blocked in 3% BSA in phosphate-buffered saline
for 30minutes at room temperature and stained with a polyclonal
rabbit anti-hCAP-18/LL-37, or a polyclonal chicken anti-hCAP18/
LL-37, a rabbit anti-NFAT (upstate), or a rabbit anti-NF-kB (Cell
Signaling Technology, Danvers, MA) antibody or preimmune serum.
After washings in phosphate-buffered saline, slides were reprobed
with secondary antibodies (FITC-conjugated anti-rabbit or anti-
chicken antibody). After subsequent washings with phosphate-
buffered saline, slides were mounted in ProLong Anti-Fade
reagent containing 4,6-diamidino-2-phenylindole (Molecular
Probes, Eugene, OR) and evaluated with an Olympus BX41
microscope (Olympus, Melville, NY) at an original magnification
of  400 or  600.
Western blot
Keratinocytes were stimulated for 24 hours with pimecrolimus or
1,25D3, their combination, or the vehicle and subsequently lysed in
ice-cold radio-immunoprecipitation buffer containing proteinase
inhibitors (Roche, Indianapolis IN). After centrifugation, equal
amounts of protein were mixed with loading buffer (0.25 M Tris
HCl, 10% SDS, 10% glycerol, 5% b-mercaptoethanol) and loaded
onto a 16% Tris-Tricine gel (GeneMate, Kaysville, UT). After
separation, proteins were blotted onto a polyvinylidene diflouride
membrane (Millipore, Billerica, MA) and blocked in 5% milk (Bio-
Rad) in TBS 0.1% Tween-20 for 1 hour at room temperature. After
washings in TBS 0.1% Tween-20, membranes were stained with a
mouse monoclonal anti-CD14 antibody (R&D Systems, Minneapo-
lis, MN), washed again in TBS 0.1% Tween-20, and reprobed with
a horseradish peroxidase-coupled goat anti-rabbit antibody
(DakoCytomation, Glostrup, Denmark). Stained protein was visua-
lized with the Western Lightning system (Perkin Elmer, Boston, MA).
Densitometric analyses were performed using ImageJ version 1.37r.
Antimicrobial assay
Antimicrobial activity of stimulated and unstimulated epithelial cells
was determined using a modified protocol described earlier
(Schauber et al., 2006). Cells were grown and stimulated in media
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without antibiotics, harvested in 100 ml sterile H2O, and sonicated
on ice for 20minutes. Cell lysates were centrifuged and supernatants
were used for antimcrobial assays. For solution killing assays,
S. aureus DmprF (Peschel et al., 2001) was grown in tryptic soy broth
(Sigma) overnight and then subcultured in 20% tryptic soy broth,
25mM NaHCO3, 1mM NaHPO4 until log phase. Approximately
20,000 bacteria (OD600 1.0 corresponds to 3.75 109 CFUsml1)
were incubated with equal protein concentrations of cell lysates at
37 1C in 20% tryptic soy broth, 25mM NaHCO3, and 1mM NaHPO4.
Bacterial growth over time was determined by optical density at
600 nm. To test whether pimecrolimus itself has antimicrobial
activity, S. aureus DmprF was directly incubated with pimecrolimus
at a dose up to 10 mM and bacterial growth was determined over time
as described.
Cytotoxicity assays
A cytotoxicity detection kit based on measurement of lactate
dehydrogenase activity (Roche) was used according the manufac-
turers’ instructions. Apoptotic and necrotic cells were quantified by
annexin V and propidium iodide staining with fluorescence-
activated cell sorting analysis (BD Pharmingen, San Jose, CA).
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